Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia

Prostate

Volumn 29, Issue 2, 1996, Pages 83-90

  Girman, Cynthia J ^a   Kolman, Christopher ^a   Liss, Charles L ^a   Bolognese, James A ^a   Binkowitz, Brace S ^a   Stoner, Elizabeth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

finasteride; patient assessment; PROSCAR; prostatic hypertrophy; quality of life

Indexed keywords

FINASTERIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SEXUAL FUNCTION; TREATMENT OUTCOME; URINE FLOW RATE;

EID: 0029822328     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199608)29:2<83::AID-PROS3>3.0.CO;2-I     Document Type: Article

References (33)

1. McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, Lange JL, McClennan JH, Mebust WK, Reilly NJ, Roberts RG, Sacks SA, Wasson JH: "Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8." AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, February 1994.
2. Mebust WK, Bosch R, Donovan J, Okada K, O'Leary MA, Villers A, Ackerman R, Batista JE, Boyle P, Denis L, Leplege A, Sagnier P: Symptom evaluation, quality of life and sexuality. In Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds): "Proceedings of The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH)," 1993, pp 131-138.
3. Fowler FJ Jr, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D: Symptom status and quality of life following prostatectomy. JAMA 259:3018-3022, 1988.
4. Fowler FJ Jr, Barry MJ: Quality of life assessment for evaluating benign prostatic hyperplasia treatments. An example of using a condition-specific index. Eur Urol 24(Suppl 1):24-27, 1993.
5. Barry MJ, Mulley AG, Fowler FJ, Wennberg JW: Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. JAMA 259:3010-3017, 1988.
6. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, the Measurement Committee of the American Urological Association: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549, 1993.
7. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGirdey J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, and the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191, 1992.
8. The Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291-299, 1993.
9. Rittmaster RS: Drug therapy: Finasteride. N Engl J Med 330:120-125, 1994.
10. Stoner E and Members of the Finasteride Study Group: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43:284-294, 1994.
11. Stoner E: Impact of medical intervention on the natural history of benign prostatic hyperplasia. In Garraway WM (ed) "The Epidemiology of Prostate Disease," Heidelberg: Springer-Verlag, pp 164-176, 1995.
12. Bolognese JA, Kozloff RC, Kunitz SC, Grino PB, Patrick D, Stoner E: Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate 21:247-254, 1992.
13. Cantril H: "The Pattern of Human Concerns." New Brunswick, NJ: Rutgers University Press, 1965.
14. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM: The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 150:85-89, 1993.
15. Jacobsen SJ, Girman CJ, Guess HA, Panser LA, Chute CG, Oesterling JE, Lieber MM: A population-based study of factors associated with discordance between frequency and bother of urinary symptoms. Urology 42:663-671, 1993.
16. Girman CJ, Epstein RE, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE, Lieber MM: Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44: 825-831, 1994.
17. Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM: Similar level of urologie symptoms have similar impact in Scottish and American men - Although Scots report less symptoms. J Urol 150:1701-1705, 1993.
18. Garraway WM, Russell EBAW, Lee RJ, Collins GN, McKelvie GB, Hehir M, Rogers ACN, Simpson RJ: Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Brit J Gen Pract 43:318-321, 1993.
19. Tsang KK, Garraway WM: Impact of benign prostatic hyperplasia on general well-being of men. Prostate 23: 1-7, 1993.
20. Tsang KK, Garraway WM: Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Aging 23:360-364, 1994.
21. Sagnier PP, Macfarlane G, Teillac P, Botto H, Richard F, Boyle P: Impact of symptoms of prostatism on bothersomeness and quality of life of men in the French community. J Urol 153:669-673, 1995.
22. Fowler FJ: Patient reports of symptoms and quality of life following prostate surgery. Eur Urol 20 (Suppl 2): 44-49, 1991.
23. Guyatt GH, Feeney DH, Patrick DL: Measuring health-related quality of life. Ann Inter Med 118:622-629, 1993.
24. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM. Schwartz S, Patrick D: Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 45:1431-1445, 1992.
25. Epstein RS, Deverka PA, Chute CG, Lieber MM, Oesterling JE, Panser L, Schwartz SW, Guess HA, Patrick D: Urinary symptoms and quality of life questions indicative of obstructive benign prostatic hyperplasia. Results of a pilot study. Urology 38(Suppl 1):20-26, 1991.
26. Jacobsen SJ, Guess HA, Panser LA, Girman CJ, Chute CG, Oesterling JE, Lieber MM: Health care seeking: a population-based study of health care-seeking behavior for treatment of urinary symptoms. Arch Fam Med 2:729-735, 1993.
27. The Department of Veterans Affairs Cooperative Study of Transurethral Resection for Benign Prostatic Hyperplasia: A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 150:1696-1700, 1993.
28. Guess HA: Measuring disease-specific quality of life in men with benign prostatic hyperplasia. In Spilker B (ed): "Quality of Life and Pharmacoeconomics in Clinical Trials." New York: Lippincott-Raven Publishers, pp 945-952, 1995.
29. Guess HA, Jacobsen SJ, Girman CJ, Oesterling JE, Chute CG, Panser LA, Lieber MM: The role of community-based longitudinal studies in evaluating treatment effects - Example: Benign prostatic hyperplasia. Med Care 33(Suppl):A526-A535, 1995.
30. Pocock SJ: A perspective on the role of quality of life assessment in clinical trials. Controlled Clin Trials 12: 257S-265S, 1991.
31. Wilson IB, Cleary PD: Linking clinical variables with health-realted quality of life. JAMA 273:59-65, 1995.
32. Patrick DL, Deyo RA: Generic and disease-specific measures in assessing health status and quality of life. Med Care 27(Suppl):S217-S231, 1989.
33. Lukacs B, McCarthy C, Grange JC, and the QOL BPH Study Group in General Practice: Long-term quality of life in patients with benign prostatic hypertrophy: Preliminary results of a cohort survey of 7,093 patients treated with alpha-1-adrenergic blocker, Alfuzosin. Eur Urol 24(Suppl 1):34-40, 1993.